Syntagon Company Profile

03:05 EDT 19th September 2018 | BioPortfolio

News Articles [4 Associated News Articles listed on BioPortfolio]

Ardena Strengthens API Offering

CDMO acquires Syntagon, maker of novel APIs and excipients

Ardena continues M&A strategy with CMO buy

CDMO Ardena has added drug product capabilities with the purchase of active pharmaceutical ingredient and excipient-focused Syntagon.

Ardena acquires Syntagon

Contract development and manufacturing organisation acquires a specialist contract manufacturer of novel active pharmaceutical ingredients and excipients, strengthening its API offering

CDMO acquires manufacturer of novel APIs and excipients

Ardena, a contract development and manufacturing organisation (CDMO), has acquired Syntagon, a contract manufacturer of novel active pharmaceutical ingredients (APIs) and excipients.

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [0 Results]


More Information about "Syntagon" on BioPortfolio

We have published hundreds of Syntagon news stories on BioPortfolio along with dozens of Syntagon Clinical Trials and PubMed Articles about Syntagon for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Syntagon Companies in our database. You can also find out about relevant Syntagon Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record